Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TOVX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTheriva stockholder meeting fails to achieve quorum, triggering 60-day re-vote cycle
Filed June 5, 2026 · Period ending June 5, 2026 · ~1 min read
Key Changes
-
high
Special meeting on June 5 failed to reach quorum, preventing vote on warrant exercise proposal that would authorize issuance of up to 16.2 million shares—roughly 16% potential dilution remains unresolved.
Item 8.01 verify on EDGAR → -
high
Company contractually obligated to hold new stockholder meetings every 60 days until approval obtained or warrants expire, creating ongoing administrative costs and uncertainty.
Item 8.01 verify on EDGAR → -
medium
Warrant inducement agreement from October 2025 requires stockholder approval for exercise shares; failure to obtain approval could impact warrant holder relations and company's ability to raise capital.
Item 8.01 verify on EDGAR →
Summary
Theriva Biologics failed to achieve quorum at its June 5 special stockholder meeting, preventing a vote on authorizing up to 16.2 million shares for warrant exercises.
The company had agreed in October 2025 to seek this approval as part of a warrant inducement deal with institutional investors, and the failed meeting triggers a contractual requirement to hold repeat votes every 60 days until approval is secured or the warrants expire.
For retail holders, this creates two immediate concerns: first, the potential dilution of roughly 16% remains unresolved and will hang over the stock until shareholders approve it. Second, the repeated meeting cycle suggests either low shareholder engagement or possible opposition to the dilution, both troubling signals. The company will incur ongoing proxy costs and management distraction with each 60-day cycle. Watch for the next meeting notice, likely within 60 days. If quorum fails again or the proposal is voted down, it could signal deeper governance issues or shareholder dissatisfaction that may affect the company's ability to execute its capital strategy.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
At that time, there were not present or represented by proxy a sufficient number of shares of the Company’s common stock to constitute a quorum. As a result, the Company was not able to convene the Special Meeting.
The company's June 5, 2026 Special Meeting of Stockholders failed to achieve the minimum number of shares needed for a quorum, preventing the meeting from proceeding. The company will need to schedule a new stockholder meeting to vote on the warrant exercise proposal and adjournment proposal previously disclosed in the April 30, 2026 proxy statement.
Added in current filing · verify on EDGAR →
unless waived by the investors, the Company will be required under the Inducement Agreement to continue to call an additional meeting of stockholders every 60 days thereafter to seek Stockholder Approval until the earlier of the date on which Stockholder Approval is obtained or the Warrants are no longer outstanding.
The failed quorum triggers a contractual obligation requiring the company to hold repeated stockholder meetings every 60 days until either approval is secured or the warrants are no longer outstanding. This creates an ongoing administrative and cost burden, and potential dilution of up to 16.2 million shares remains unresolved pending stockholder approval.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify